Altus Pharmaceuticals, a biopharmaceutical company engaged in the development of protein therapies for chronic gastrointestinal and metabolic disorders, priced its offering of 7 million shares at $15, the mid-point of its $14-$16 range. Merrill Lynch and Morgan Stanley acted as joint book-running managers for the IPO. The stock is expected to commence trading on the Nasdaq under the ticker symbol "ALTU" on Thursday.
